VEGFA and cancer: Cardiovascular monitoring strategies have been defined in adults exposed to cancer drugs associated with a high risk of cardiotoxicity, including anthracyclines, human epidermal growth factor-2 inhibitors, vascular endothelial growth factor inhibitors, Bcr-Abl kinase inhibitors, proteasome inhibitors, immune checkpoint inhibitors and ibrutinib.